Startups
ProMIS Neurosciences
Cambridge, Massachusetts, United States · Toronto, Ontario, Canada
Biotechnology company developing antibodies and vaccines targeting toxic misfolded proteins in neurodegenerative diseases. Its EpiSelect platform combines protein physics, computational prediction and biology to identify disease-specific epitopes. Lead antibody PMN310 is being studied in Alzheimer's disease; earlier programs target TDP-43 in ALS and frontotemporal dementia and alpha-synuclein in Parkinson's and related disorders.
Founded 2004
Team
Alain DagherScientific Advisory Board Member |
Andre StrydomScientific Advisory Board Member |
Carsten KorthScientific Advisory Board Member |
Cheryl WellingtonScientific Advisory Board Member |
 Daniel GeffkenChief Financial Officer |
 David WishartChief Physics Officer |
 Eugene WilliamsChairman and Co-Founder |
Guy RouleauScientific Advisory Board Member |
 Henrik ZetterbergClinical Advisory Board Member |
 Howard FillitClinical Advisory Board Member |
 Ivana RubinoChief Commercial Officer |
 Johanne KaplanChief Development Officer |
 Josh Mandel-BrehmIndependent Director |
 Larry AltstielChief Medical Officer |
 Maggie ShafmasterLead Independent Director |
 Michael WeinerClinical Advisory Board Member |
Michelle L. HastingsScientific Advisory Board Member |
 Neil CashmanChief Scientific Officer and Co-founder · Board Director · Scientific Advisory Board Co-Chair |
 Neil K. WarmaPresident and Chief Executive Officer · Board Director |
Sharon CohenScientific Advisory Board Member |
 Slanix Paul AlexIndependent Director |
 Suzanne HendrixClinical Advisory Board Member |
William C. MobleyScientific Advisory Board Member |
 William WymanIndependent Director |